Website: Penn State Cancer Institute
Linked In
You Tube
Penn State Cancer Institute
Trials at this location:
HCRN-BRE17-141
An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER2-Positive Breast Cancers
Status: Open to Accrual
HCRN-BRE20-468
A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Status: Open to Accrual
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter